Watson JM, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter RA and Read KD (2009). Receptor occupancy and brain free fraction. Drug Metabolism and Disposition 37, 753-760 Read KD and Braggio S (2010). Assessing brain free fraction in early drug discovery. Expert Opin. Drug Metab. Toxicol. 6 (3), 337-344 Frearson, J. A.; Brand, S.; McElroy, S. P.; Cleghorn, L. A. T.; Smid, O.; Stojanovski, L.; Price, H. P.; Guther, M. L. S.; Torrie, L. S.; Robinson, D. A.; Hallyburton, I.; Mpamhanga, C. P.; Brannigan, J. A.; Wilkinson, A. J.; Hodgkinson, M.; Hui, R.; Qiu, W.; Raimi, O. G.; Van Aalten, D. M. F.; Brenk, R.; Gilbert, I. H.; Read, K. D.; Fairlamb, A. H.; Ferguson, M. A. J.; Smith, D. F.; Wyatt, P. G. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732 Sokolova A, Wyllie S, Patterson S, Oza SL, Read KD and Fairlamb AH (2010) Cross-resistance to nitro drugs and implications for treatment of human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy 54(7), 2893-2900 Jones DC, Hallyburton I, Stojanovski L, Read KD, Frearson JA and Fairlamb AH (2010). Identification of a k-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem. Pharmacol. 80 (10), 1478-1486 Kajbaf M, Longhi R, Montanari D, Vinco F., Rigo M., Fontana S and Read KD (2011) A comparative study of the CYP450 inhibition potential of marketed drugs using two fluorescence based assay platforms routinely used in the pharmaceutical industry (2011) Drug Metabolism Letters 5 (1), 30-39 Wyatt PG, Gilbert IH, Read KD and Fairlamb AH (2011). Target validation: Linking target and chemical properties to desired product profile. Current Topics in Med. Chem. 11, 1275-1283 Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M (2012). Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs. J. Cereb Blood Flow Metab. 32(5):874-83 Wyllie S, Patterson S, Stojanovski L, Simeons FRC, Norval S, Kime R, Read KD and Fairlamb AH (2012). The Anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis. Science Translational Medicine, 4, 1-7 Brand, S.; Cleghorn, L. A. T.; McElroy, S. P.; Robinson, D. A.; Smith, V. C.; Hallyburton, I.; Harrison, J. R.; Norcross, N. R.; Norval, S.; Spinks, S.; Stojanovski, L.; Torrie, L. S.; Frearson, J. A.; Brenk, R.; Fairlamb, A. H.; Ferguson, M. A. J.; Read, K. D.; Wyatt, P. G.; Gilbert, I. H. Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. J. Med. Chem. 2012, 55, 140-152 Besnard J, Ruda, GF, Setola V, Abecassis K, Rodriguiz RM, Huang XP, Norval S, Sassano MF, Shin AI, Webster LA, Simeons FRC, Stojanovski L, Prat A, Seidah NG, Constam DB, Bickerton GR, Read KD, Wetsel WC, Gilbert IH and Hopkins A (2012) Automated design of ligands to polypharmacological Profiles. Nature 492 (7428), 215-220 Brand S , Norcross NR , Thompson S , Harrison JR , Smith VC , Robinson DA , Torrie LS , McElroy SP, Hallyburton I, Norval S , Scullion P , Stojanovski L , Simeons FRC , van Aalten D , Frearson JA ,Brenk R , Fairlamb AH , Ferguson MAJ , Wyatt PG , Gilbert IH and Read KD (2014). LeadOptimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors:Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 HumanAfrican Trypanosomiasis. J. Med.Chem. 57, 9855-9869